Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
This study has been completed.
Information provided by (Responsible Party):
First received: April 29, 2009
Last updated: November 9, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2016|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||August 22, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013 Jan;14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8.